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Abstract.
AIM: To assess and compare the roles of plasma and urine concentrations of neutrophil gelatinase associated lipocalin (NGAL)
and Cystatin C for early diagnosis of septic acute kidney injury (AKI) in adult critically ill patients.
METHODS: Patients were divided into three groups as sepsis-non AKI, sepsis-AKI and non sepsis-non AKI. Plasma samples
for NGAL and Cystatin C were determined on admission and on alternate days and urinary samples were collected for every day
until ICU discharge.
RESULTS: One hundred fifty one patients were studied; 66 in sepsis-non AKI, 63 in sepsis-AKI, 22 in non-sepsis-non-AKI
groups. Although plasma NGAL performed less well (AUC 0.44), urinary NGAL showed significant discrimination for AKI
diagnosis (AUC 0.80) with a threshold value of 29.5 ng/ml (88% sensitivity, 73% specificity). Both plasma and urine Cystatin C
worked well for the diagnosis of AKI (AUC 0.82 and 0.86, thresholds 1.5 and 0.106 mg/L respectively).
CONCLUSION: Plasma and urinary Cystatin C and urinary NGAL are useful markers in predicting AKI in septic critically ill
patients. Plasma NGAL raises in patients with sepsis in the absence of AKI and should be used with caution as a marker of AKI
in septic ICU patients.
Keywords: NGAL protein, human, Cystatin C, Acute kidney injury, biomarkers, sepsis, Intensive Care Units, predictive value of
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1. Introduction
Acute kidney injury (AKI) is a common clinical
problem in critically ill patients [1–3]. It has quite high
prevalence among the intensive care unit (ICU) pa-
tients varying between 30–50% with an attributed mor-
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tality rate varying between 28–90% [1–4]. Approxi-
mately 50% of all AKI is considered to be associated
with sepsis and 15–20% of all patients admitted to
ICUs are septic AKI patients [2].
According to RIFLE or AKIN criteria, the current
diagnosis of AKI is mainly based on diagnostic in-
creases in serum creatinine indicating the loss of ex-
cretory renal function [5]. In septic AKI, serum crea-
tinine doesn’t accurately reflect the glomerular filtra-
tion rate (GFR), because the patient is not in steady
state condition. Furthermore serum creatinine is also
ISSN 0278-0240/13/$27.50 c© 2013 – IOS Press and the authors. All rights reserved
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influenced by tubular creatinine secretion and non-
renal factors such as muscle mass, liver function and
non-renal gastrointestinal elimination [6–8]. Besides,
Doi et al., found in their animal study that sepsis dra-
matically reduces the production of creatinine without
changes in body weight, hematocrit and extracellular
fluid volume [9].
Many clinical studies have demonstrated the abil-
ity of NGAL and Cystatin C to allow early identifica-
tion of AKI i.e., 48 hours earlier than plasma creatinine
level. They are investigated in different clinical settings
including cardiac surgery [10], contrast agent use [11],
critically ill patients [12–21] and in emergency depart-
ment [22].
Among the studies performed in ICUs with critically
ill patients there are still conflicting results about the
use of NGAL and Cystatin C for the early diagnosis
of AKI. Because SIRS, severe sepsis and septic shock
are known to increase plasma NGAL and Cystatin C
levels in the absence of AKI [17]. But, whether sepsis
affects the specificity of urine NGAL and Cystatin C as
an early AKI marker is still unclear. So in this study we
aimed to assess and compare the utility of plasma and
urine concentrations of NGAL and Cystatin C for early
diagnosis of septic AKI in adult critically ill patients.
2. Methods
A prospective cohort study, performed in a seven
beds pulmonary ICU of a university hospital between
January 2008 and March 2010. The ethic committee
of our institution approved the study and the proce-
dures performed in this study were in accordance with
the Helsinki Declaration. An informed consent was ob-




The patients who were > 18 years old without
known previous renal disease, who were admitted to
our ICU and who did not have any one of the exclusion
criteria were included in the study consecutively.
The patients who were included in the study were
grouped into three as; sepsis and non-AKI group; sep-
sis and AKI group and non-sepsis, non-AKI group.
2.1.2. Exclusion criteria
It was shown previously in many clinical studies and
has been accepted that NGAL and Cystatin C levels
increase in different clinical settings leading to AKI
development [10–22]. Since the aim of this study is
to define the roles of Cystatin C and NGAL in pre-
dicting septic AKI development, the patients who had
other risk factors, rather than sepsis, that would lead
to AKI and increase the Cystatin C and NGAL levels
(i.e., nonseptic-AKI patients) were excluded from the
study. Patients who were excluded were the ones with
the diagnosis of:
1) Chronic kidney disease,
2) Urinary tract infection at admission,
3) AKI at the time of admission
4) Prerenal and postrenal causes of AKI
5) Being exposed to radiocontrast dye or nephro-
toxic drugs (aminoglycoside, colistin, ampho-
tericin) within at least one week before the ad-
mission to ICU.
Although initially included in the study, the ones
who had urine and blood samples that could not be
studied in laboratory for Cystatin C and NGAL due to
technical problems were also excluded at the end of the
study.
2.2. Definitions
Acute kidney injury (AKI), risk and failure were
defined according to RIFLE criteria [5,23]. The daily
glomerular filtration rate was evaluated and also hourly
urine samples were collected and the RIFLE class was
defined based on the worst of either glomerular filtra-
tion criteria or urine output criteria. Glomerular filtra-
tion criteria were calculated as an increase of serum
creatinine above the baseline serum creatinine level.
Among the patients who had previous medical records,
the lowest serum creatinine level within the previous
one or two years was accepted as baseline. Among the
ones who did not have any previous medical records
and who did not have chronic kidney disease requir-
ing dialysis, the admission serum creatinine level (if it
is within normal range) was accepted as baseline and
then followed for the development of AKI. Acute kid-
ney injury should be both abrupt (within 1–7 days) and
sustained (more than 24 hours). In order to evaluate
whether Cystatin C and NGAL can be used as an early
predictor of AKI, all patients with ‘injury’ and ‘failure’
were included in the statistical analysis and evaluated
in the group ‘sepsis and AKI’.
Chronic kidney disease was defined according to
the definition of National Kidney Foundation as kid-
ney damage or glomerular filtration rate (GFR) <
60 ml/min/1.73 m2 for three or more months, irrespec-
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tive of the cause [24]. For the evaluation of chronic
kidney disease the previous medical records of the pa-
tients were used. The ones who were included to a rou-
tine dialysis program (2–3 times/week) before admis-
sion were also accepted as having chronic kidney dis-
ease and excluded from the study.
Sepsis and septic shock were defined according to
consensus guidelines [25].
The possible underlying causes of sepsis such as
community acquired pneumonia (CAP), ventilator as-
sociated pneumonia (VAP), hospital associated pneu-
monia (HAP), catheter related infections, blood stream
related infections, bacteremia, urinary infections, ab-
dominal and wound infections were defined according
to consensus guidelines [26].
Patients were considered to have steroid treatment if
they have received 40–80 mg/day of systemic methyl-
prednisolone or equivalent therapy for at least five
days.
2.3. Data collected
All data were prospectively collected on standard-
ized study forms. Data variables collected included
the demographic characteristics (age, gender, and body
weight), admission diagnosis, and comorbidities. Ad-
mission baseline creatinine and BUN levels, leukocyte
count, erythrocyte sedimentation rate, CRP, vital signs
(heart rate, temperature, mean arterial blood pressure)
were also noted for the evaluation of sepsis and re-
nal failure. Numerous clinical and physiological de-
tails were also collected, including those that compose
the APACHE II, severity of organ failure assessment
(SOFA), pneumonia severity index (PSI) and Charlson
comorbidity scores [27–30]. During ICU stay, daily
creatinine, BUN, total daily fluid intake, total daily
urinary output, medications (vasoactive drugs, steroids
antibiotics, nephrotoxic agents) were also recorded.
The day of sepsis, etiology of sepsis, microorganisms
causing sepsis, the day of risk, injury and failure de-
velopment were recorded. Intensive care unit outcome
parameters such as duration of mechanical ventilation,
length of ICU stay, length of hospitalization and mor-
tality were also evaluated for 3 patient groups.
2.4. Sample collection and analysis
The blood samples were obtained within first
24 hours of ICU admission and then in every other
day from all patients and urine samples were col-
lected daily either from spontaneous voids or from in-
dwelling Foley catheters. Blood samples were not ob-
tained daily in order not to cause anemia in patients
who had longer ICU stay. In patients who did not
develop AKI, samples were collected until ICU dis-
charge. In patients who develop AKI sample collec-
tion was stopped at the day of AKI. After being cen-
trifuged at 5000 bpm for 15 minutes, the urine and
blood supernatant samples were aliquoted into 1.8 ml
eppendorf tubes and frozen within 2 hours of collec-
tion were at −80◦C. Plasma and urine NGAL lev-
els were studied from these collected samples with
enzyme linked immunosorbent assay method (Human
Lipocalin-2/NGAL ELISA BiovendorTM). Plasma and
urine Cystatin C levels were analyzed with particle en-
hanced immunonephelometric assay with BNII neph-
elometer (Dade Behring GmbH, Marburg, Germany).
For the patients who developed AKI the results were
numerated as giving ‘0’ to the day of AKI and then
the samples were assessed as −2, −4, −6, −8, −10,
−12 etc. days before the development of AKI. Then
the value that is at least 20% higher than the baseline
was taken into consideration for the statistical analysis
and its’ day was noted. For the patients without AKI
just the course of NGAL and Cystatin C were followed
during their whole stay in the ICU department and a
mean value was calculated for the statistical analysis.
2.5. Statistical analysis
SPSS for Windows 15.0 software was used for the
statistical analysis of the results (SPSS for Windows;
Chicago, IL, USA). Results are presented as mean ±
SD and percentiles or median (range) values. The in-
dependent samples t-test, the Chi square and Mann-
Whitney U tests were used for comparison of the cat-
egorical and continuous variables. NGAL and Cys-
tatin C values and other parameters of non-sepsis non-
AKI, sepsis and non-AKI, sepsis and AKI groups were
evaluated and compared with Kruskal Wallis one–way
analysis of variance (ANOVA) analysis. P < 0.05 was
considered statistically significant. In order to identify
the cutoff values of urine and plasma NGAL and Cys-
tatin C tests for the prediction of septic AKI, receiver-
operating characteristic (ROC) curves were used and
specificities and sensitivities of the tests were assessed
using the area under ROC curves (AUC).
3. Results
3.1. Study population characteristics
Between January, 2008 and March, 2010 a total of
384 patients were evaluated but 151 of them were in-
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Fig. 1. Flow-chart showing numbers of screened/excluded/analyzed patients and study groups.
cluded in the study according to inclusion and ex-
clusion criteria (Fig. 1). Among them, 66 (44%) pa-
tients included in ‘sepsis’ group; 63 (42%) patients in-
cluded in ‘sepsis and AKI’ group and 22 (15%) pa-
tients included in ‘non sepsis non AKI’ group. Totally,
978 samples (326 blood and 652 urine) were used for
NGAL and 780 samples (260 blood and 520 urine)
were used for Cystatin C analysis.
During their stay in intensive care unit, ‘risk’ for re-
nal failure was developed in 63 (42%) patients at 5 ±
7 days of their ICU admissions; ‘injury’ (AKI) devel-
oped in 54 (36%) patients at 9 ± 8 days of their ICU
admissions and ‘failure’ developed in 15 (10%) pa-
tients at 12 ± 11 days of their ICU admissions. Dialy-
sis was performed in only 4 (3%) patients. A total of 63
(%42) patients developing both ‘injury’ and ‘failure’
were grouped as ‘sepsis and AKI’ group.
The demographic properties of the patient groups,
their admission diagnosis, comorbidities and ICU out-
comes were compared and summarized in Table 1. A
remarkable result that was presented in Table 1 is that;
the length of MV, the length of hospital and ICU stay
and also the rate of mortality were significantly higher
in ‘sepsis and AKI’ patient group when compared with
the ‘sepsis non AKI’ patient group (p < 0.005). When
the factors affecting mortality in the study group was
evaluated the significant factors affecting the mortal-
ity was found as malignancy, sepsis, septic shock, any
degree of renal function impairment (risk, AKI and
failure), length of MV, ICU stay and hospitalization,
higher CRP levels, higher urine NGAL and Cystatin
C levels and serum Cystatin C in the univariate anal-
ysis (p < 0.005). In the multivariate logistic regres-
sion analysis the presence of septic shock (P = 0.010,
OR:13, %95 CI: 1.8–86.9) and higher serum Cystatin
C levels (P = 0.005, OR = 16, %95 CI: 2.3–108.9)
were identified as independent predictors of mortal-
ity. Sepsis was existed in 129 (%85) patients while
55 (%36) of them developed septic shock. Etiology of
sepsis, sepsis related scores (SOFA, PSI), microbiolog-
ical analysis were given in Table 2.
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Table 1
Demographic properties, admission diagnosis, comorbidities and ICU outcomes of the patient groups
Parameter Non-sepsis non-AKI Sepsis and non-AKI Sepsis and AKI P
N: 22 mean ± SD N:66 mean ± SD N:63 mean ± SD
Age, years 66 ± 10 67 ± 15 70 ± 13 0.200
Gender (male), n (%) 15 (68) 42 (64) 41 (45) 0.927
Admission diagnosis of the patients, n (%)
Pneumonia∗ 1 (5)a 29 (44) 25 (40)a 0.014
COPD attack 5 (23) 16 (24) 15 (24) 0.815
Congestive heart failure 5 (23)a,c 2 (3)c 0a 0.018
Sleep disorder∗∗ 6 (27)a,c 1 (2)c 1 (2)a 0.001
Restrictive pulmonary disease 3 (14) 9 (14) 7 (11) 0.704
Pulmonary thromboembolism 1 (5) 2 (3) 3 (5) 0.756
Malignancy 1 (5) 3 (5) 8 (13) 0.365
Bronchiectasis 0 4 (6) 3 (5) 0.352
Trauma 0 0 1(2) −
Comorbidities of the patients, n(%)
COPD 12 (55) 30 (46) 28 (44) 0.702
Congestive Heart Failure 11 (50) 22 (33) 22 (35) 0.353
Hypertension 13 (59) 30 (46) 23 (37) 0.172
Diabetes Mellitus 5 (23) 21 (32) 18 (29) 0.713
Immunosupression 0 6 (9) 5 (8) 0.347
Malignancy 1 (5) 9 (14) 15(24) 0.078
APACHE II 17 ± 4a 20 ± 7 22 ± 6a 0.014
Charlson 2 ± 1 2 ± 1 3 ± 3 0.635
Basal creatinine level, mg/dl 0.7 ± 0.1 0.8 ± 1.02 0.9 ± 0.9 0.832
Admission creatinine level, mg/dl 0.9 ± 0.17a 0.9 ± 0.25b 1.2 ± 0.6a,b 0.001
Steroid use, n (%) 13 (59)a,c 55 (83)c 54 (86)a 0.019
Length of mechanical ventilation, days 2 ± 7a,c 7 ± 9b,c 16 ± 16a,b 0.001
Length of ICU stay, days 12 ± 8a 15 ± 10b 22 ± 17a,b 0.001
Length of hospital stay, days 13 ± 6a 18 ± 11b 24 ± 17a,b 0.002
Mortality, n (%) 1 (5)a,c 16 (24)b,c 42 (67)a,b 0.001
∗Pneumonia; including community acquired pneumonia, immunosupressive pneumonia, healthcare associated pneumonia, hospital acquired
pneumonia; ∗∗Sleep disorder: Obstructive sleep apnea, obesity hypoventilation syndrome, overlap syndrome; ∗∗∗a < 0.05 between nonseptic
nonAKI group and septicAKI group; bp < 0.05 between sepsis group and septicAKI group; cp < 0.05 between nonseptic nonAKI group and
sepsis group.
3.2. NGAL and Cystatic C analysis results
The urine and plasma NGAL and Cystatin C lev-
els were compared between the 3 groups and no sta-
tistically significant difference was found for plasma
NGAL levels. On the other hand urine NGAL levels,
serum and urine Cystatin C levels were found signifi-
cantly elevated in septic AKI patients when compared
with non sepsis-non AKI and sepsis-non AKI patient
groups (p = 0.001) (Table 3). The changes in plasma
and urine NGAL and Cystatine C levels within 8 days
before the development of AKI in septic AKI patients
were shown in Figs 2 and 3. Similarly the changes in
plasma and urine NGAL and Cystatin C values within
8 days after ICU admission in non AKI patients were
summarized and shown by graphics in Figs 4 and 5.
ROC curves of plasma and urine NGAL and Cys-
tatin C for the prediction of AKI were shown in Fig. 6.
AUC for the diagnosis of AKI was 0.44 for plasma
NGAL, 0.80 for urine NGAL, 0.82 for plasma Cys-
tatin C and 0.86 for urine Cystatin C. Threshold level,
sensitivity and specificity of test determined for urine
NGAL, plasma and urine Cystatin C, but could not for
plasma NGAL levels (Table 4).
Plasma Cystatin C increased > 100% in 11 patients,
50–100% in 3 patients, < 50 % in 5 patients during
their follow up. Urine NGAL levels increased > 100%
in 2 patients, < 50% in 10 patients. Urine Cystatin C
levels increased > 100% in 5 patients, < 50% in 2 pa-
tients.
4. Discussion
This study revealed the importance of using urine
NGAL and plasma and urine cystatin C as follow
up markers of septic AKI in ICUs; on the other
hand plasma NGAL was found unsuccessful. Besides,
threshold levels were determined for both markers for
the diagnosis of septic AKI.
Acute kidney injury is an important cause of mortal-
ity and morbidity in ICUs. Our study remarkably once
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Table 2
Characteristics and etiologies of sepsis, infection and sepsis related
scores of septic patients (sepsis and non AKI group, sepsis and AKI
group)
Parameter N = 129∗
mean ± SD
Pneumonia Severity Index (PSI) score 141 ± 39
Clinical Pulmonary Infection Score (CPIS) 6 ± 2
Sequential Organ Failure Assessment (SOFA) 6 ± 3
score
C-Reactive Protein 60 ± 92
Leukocyte count 13788 ± 7134
Mean arterial pressure (mmHg) 72 ± 14
Source of sepsis∗∗, n (%)
Any pulmonary infection∗∗∗ 89 (69)
Catheter infection 27 (21)
Urinary infection 27 (14)
Wound infection 5 (4)
Microbiologic etiology, n (%)
Acinetobacter Baumanii 38 (29)
MRSA 10 (8)
Pseudomonas aeroginosa 8 (6)
Echerishia Coli 8 (6)
Candida species 6 (5)
Klebsiella 3 (2)
Enterobacter 2 (2)
Stenotrophomonas maltophilia 1 (1)
∗N: 129; since non-sepsis non-AKI patient group was excluded.
Statistics were performed among 129 septic patients; ∗∗More than
one source of sepsis was identified in some patients; ∗∗∗Ventilator
associated pneumonia, hospital acquired pneumonia, immunosup-
pressive pneumonia, health care associated pneumonia, community
acquired pneumonia and infective bronchiectasis.
again pointed out this fact as the rate of mortality and
the length of mechanical ventilation, ICU stay and hos-
pitalization were significantly higher in ‘sepsis-AKI’
patient group when compared with ‘sepsis non AKI’
patient group. This result underlines the importance of
earlier detection of AKI especially in emergency de-
partments and ICUs. With the earlier detection of AKI,
earlier interventions can be made such as fluid resus-
citation, early antibiotic initiation and restricting intra-
venous contrast dye and nephrotoxic antibiotic use. Af-
ter cardiac surgery and radiocontrast exposure the de-
velopment of AKI is expected; so follow up of NGAL
levels may be useful in early diagnosis. But in critically
ill patients it is hard to estimate the etiology and timing
of AKI development. In order to diagnose AKI earlier
than creatinine, follow up of plasma or urine NGAL
levels might be used in ICUs. Our results pointed out
that follow up of plasma NGAL was nonspecific for the
diagnosis of AKI with an AUC of 0.44 and it can also
increase during sepsis in the absence of AKI. NGAL
is an acute phase reactant and may be released from
neutrophils, macrophages and other immune cells. Fur-
thermore, any decrease in GFR resulting from AKI
Fig. 2. The change of plasma and urine NGAL levels (mean val-
ues, ng/ml) within 8 days before the development of AKI in septic
AKI patients. (Colours are visible in the online version of the article;
http://dx.doi.org/10.3233/DMA-130966)
Fig. 3. The change of plasma and urine Cystatin C levels (mean val-
ues, mg/L) within 8 days before the development of AKI in septic
AKI patients. (Colours are visible in the online version of the article;
http://dx.doi.org/10.3233/DMA-130966)
would be expected to decrease the renal clearance of
NGAL, with subsequent accumulation in the systemic
circulation. Although plasma NGAL is freely filtered
by the glomerulus, it is largely reabsorbed in the prox-
imal tubules by efficient megalin-dependent endocyto-
sis [31]. Thus, any urinary excretion of NGAL is likely
only when there is concomitant proximal renal tubular
injury. So in sepsis, although plasma NGAL levels in-
crease due to inflammation, urine NGAL increase only
in the presence of AKI [31]. As AKI often is associ-
ated with sepsis [32], this might obstruct the predictive
properties of plasma NGAL as a biomarker of AKI, at
least in the general ICU setting.
We identified that urine NGAL levels were increased
in septic patients but the increase in AKI patients was
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Table 3
Comparison of the mean plasma and urine NGAL and Cystatin C levels in three patient groups (non-sepsis non-AKI, sepsis and non-AKI, sepsis
and AKI)
Parameter Non-sepsis non-AKI Sepsis and non-AKI Sepsis and AKI P
N: 22 mean ± SD N:66 mean ± SD N:63 mean ± SD
Plasma NGAL, ng/ml 60.3 ± 37.9 63.1 ± 39.2 72.5 ± 33.1 0.244
Urine NGAL, ng/ml 17.5 ± 24.4a,c 25.9 ± 20.9b,c 56.4 ± 28.1a,b 0.001
Plasma Cystatin C, mg/L 1.1 ± 0.31a,c 1.4 ± 0.38b,c 2.37 ± 1.21a,b 0.001
Urine Cystatin C, mg/L 0.04 ± 0.07a,c 0.11 ± 0.11b,c 0.92 ± 0.98a.b 0.001
∗a; p < 0.05 between nonseptic nonAKI group and septicAKI group; b; p < 0.05 between sepsis group and septicAKI group; c; p < 0.05
between nonseptic nonAKI group and sepsis group.
Table 4
Threshold levels, sensitivity and specificity of plasma and urinary NGAL and Cystatin C levels for predicting AKI development
AUC p Threshold value Sensitivity Specificity
Plasma NGAL (ng/ml) 0.44 0.44
Urine NGAL (ng/ml) 0.80 0.001 29.5 0.88 0.73
Plasma Cystatin C (mg/l) 0.82 0.001 1.5 0.73 0.68
Urine Cystatin C(mg/l) 0.86 0.001 0.106 0.85 0.80
Fig. 4. The change of plasma and urine NGAL levels (mean val-
ues, ng/ml) within 8 days after admission to ICU in septic nonAKI
patients. (Colours are visible in the online version of the article;
http://dx.doi.org/10.3233/DMA-130966)
much higher. There was a significant difference in
urine NGAL levels of septic and septic-AKI patients
and a threshold level can be useful in discriminat-
ing septic non-AKI and septic-AKI patients in ICUs.
We determined a threshold value of 29.5 ng/ml for
urine NGAL in order to diagnose AKI in septic criti-
cally ill patients. Urine NGAL measurement is an easy
and a noninvasive method that necessitates only spon-
taneously produced urine sample. With the evolving
technology it is now possible to measure urine NGAL
at bed side with assay kits [6]. Since no blood is drawn
daily, it will not contribute the anemia in ICUs.
Our results about the diagnostic role of NGAL in
septic AKI patients were compatible with the results of
Martensson et al. [17]. They stated in their study that
in septic ICU patients, although plasma NGAL levels
Fig. 5. The change of plasma and urine Cystatin C levels (mean
values, mg/L) within 8 days after admission to ICU in septic non-
AKI patients. (Colours are visible in the online version of the article;
http://dx.doi.org/10.3233/DMA-130966)
were not successful in predicting AKI development,
urine NGAL levels were much more successful with
an AUC of 0.86. They concluded that urine NGAL is
probably a more robust marker of AKI than plasma
NGAL in patients with septic shock since urine NGAL
levels remain within normal limits even when plasma
levels are high and signs of AKI are absent. Previ-
ous studies on pediatric ICU patients have also shown
that serum NGAL is a nonspecific predictor [19] and
urine NGAL is a good predictor of AKI [13]. Bagshaw
et al., also studied plasma and urine NGAL levels in
early diagnosis of AKI in septic patients [15]. They
compared septic and nonseptic AKI patients and found
higher plasma and urine NGAL levels in septic pa-
tients when compared with the nonseptic ones. Since
their both groups had AKI, either septic or nonsep-
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Fig. 6. The ROC curve showing the performance of plasma and urine NGAL and Cystatin C levels in predicting septic AKI. AUC for plasma
and urine NGAL and Cystatin C levels were also presented under the graphic. Threshold values were identified as 29.5 ng/ml for urine
NGAL, 1.5 mg/l for plasma Cystatin C and 0.106 mg/l for urine Cystatin C. (Colours are visible in the online version of the article; http://dx.
doi.org/10.3233/DMA-130966)
tic, they showed no superiority of urine NGAL over
plasma NGAL [15].
We identified a threshold value of 1.5 mg/L for
plasma Cystatin C for the diagnosis of septic AKI with
a sensitivity of 73% and specificity of 68%. For urine
Cystatin C, 0.11 mg/L was the threshold level with a
sensitivity of 85% and specificity of 80%. Nejad et al.
in their heterogenous adult ICU study population eval-
uated the use of plasma Cystatin C in early diagnosis of
AKI and they identified that plasma Cystatin C levels
identified AKI 5.8 hours earlier than creatinine [33].
This was median 2 days before in our study. Same re-
searchers also studied urine Cystatin C in their studies
and AUC for the diagnosis of sepsis was identified as
0.80, for the diagnosis of AKI was 0.70 [33]. In this
study a threshold level of 0.12 mg/L was identified for
urine Cystatin C levels and this was very similar with
our findings. In contrast to our study Nejad et al. identi-
fied no difference in urine Cystatin C levels of patients
with sepsis and septic AKI. They explained their find-
ings with the possibility of masking of urine Cystatin
C increase in AKI with the increased levels in sepsis
and as it was shown in an experimental study of Doi
et al. sepsis can decrease creatinin levels; if AKI defi-
nition was made according to an increase in creatinine
level the sensitivity of urine Cystatin C decreases [9].
The authors suggested that a new threshold for urine
Cystatin C can be defined for the prediction of AKI in
these septic patients. But their results can also be due
to not exactly dividing the groups.
The use of Cystatin C as a marker of AKI must be
done with caution in critically ill patients. Because in
these patients there are many factors that can affect the
plasma and urine levels of Cystatin C such as abnor-
mal thyroid function, use of immunosupressive therapy
(corticosteroids), sepsis, cardiac failure, renal injury,
chronic renal failure and nephrotoxic drug use [34].
We excluded the patients with chronic kidney disease
and receiving nephrotoxic drugs. As a limitation we
did not exclude patients with cardiac problems but by
having serial measurements of plasma and urine lev-
els of Cystatin C and NGAL we partially eliminate this
disadvantage. We also did not exclude patients receiv-
ing steroids since they were too much in number. But
we evaluated the effects of steroid use on Cystatin C
levels. Steroid use was significantly higher both in sep-
tic and septic AKI groups when compared with the non
sepsis-non AKI group. But since there were no differ-
ence between the rates of steroid use in septic non-
AKI and septic-AKI groups, the significant increase in
plasma and urinary Cystatin C levels in septic AKI pa-
tients could not be explained only by the steroid use.
As another limitation we did not evaluate the thyroid
function tests which are also reported to be affecting
Cystatin C levels.
In addition to limitations mentioned above there are
also a few more important limitations of this study.
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First of all, it is a single center study with low patient
number. Secondly, urine NGAL and Cystatin C was
not expressed as ng/mg creatinine in this study. This
expression may be useful to standardize and correct for
changes in urine concentration. On the other hand it is
not practical and cost effective for our study and also
for daily routine of ICUs to collect urine samples for
24 hours and to study daily creatinine levels.
5. Conclusion
As a conclusion; plasma and urine Cystatin C and
urine NGAL can be used for the early diagnosis of
AKI; on the other hand plasma NGAL should be used
with caution since it can increase in septic patients in
the absence of AKI in critically ill patients. This find-
ing is quite much important for ICU patients and if
this study will be supported with further studies, sim-
ple urine tests can be used noninvasively for the moni-
torization of AKI. In the future with new evolutions it
might be easier to perform urine tests at bedside both
for NGAL and Cystatin C.
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